# A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

> **NCT04252846** · — · COMPLETED · sponsor: **Eisai Limited** · enrollment: 191 (actual)

## Conditions studied

- Idiopathic Generalized Epilepsy
- Partial Onset Seizures
- Generalised Tonic-Clonic Seizures

## Interventions

- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT04252846
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2023-01-12
- **Final completion:** 2023-01-12
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252846, "A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04252846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*